Zura Bio Limited
18.20%
19,699,071
1855644
G9TY5A101
Feb 25, 2026
Mar 2, 2026, 05:53 PM
Reporting Persons (4)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| AI Biotechnology LLC | Other | 18.20% | 19,699,071 | 0 | 19,699,071 |
| Access Industries Holdings LLC | Other | 18.20% | 19,699,071 | 0 | 19,699,071 |
| Access Industries Management, LLC | Other | 18.20% | 19,699,071 | 0 | 19,699,071 |
| Len Blavatnik | Individual | 18.20% | 19,699,071 | 0 | 19,699,071 |
Disclosure Items (3)
Class A Ordinary Shares, par value $0.0001 per share
Zura Bio Limited
1489 W. Warm Springs Rd. #110, Henderson, NV, 89014
Item 3 of the Schedule 13D is hereby amended and supplemented by adding the following: On February 26, 2026, AIB purchased 2,000,000 Class A Ordinary Shares at a purchase price of $6.25 per share pursuant to a registered offering of Class A Ordinary Shares by the Issuer. AIB funded this purchase using capital contributed from affiliated entities, which funded that capital using cash on hand.
Item 5 of the Schedule 13D is hereby amended and restated as follows: The responses of each of the Reporting Persons with respect to Rows 11, 12, and 13 of the cover pages of this Schedule 13D that relate to the aggregate number and percentage of Class A Ordinary Shares (including but not limited to footnotes to such information) are incorporated herein by reference. The Private Placement Warrants may not be exercised if the aggregate number of Class A Ordinary Shares beneficially owned by the holder thereof immediately following such exercise would exceed 9.99% of the Class A Ordinary Shares outstanding, as calculated under Rule 13d-3 of the Securities Exchange Act of 1934, as amended; provided, however, that AIB may increase or decrease the foregoing beneficial ownership limitation by giving notice to the Issuer (such notice not to be effective until the sixty-first day after the notice is delivered to the Issuer), but not to exceed any percentage in excess of 19.99% (such limitations, the "Beneficial Ownership Blocker"). As of the date of this filing, and pursuant to the Beneficial Ownership Blocker, 3,255,460 Class A Ordinary Shares are issuable at any time or times upon the partial conversion of Private Placement Warrants and 13,146,346 Class A Ordinary Shares are issuable upon the conversion of Private Placement Warrants, if AIB delivered notice to the Issuer to increase the beneficial ownership limitation to 19.99% (such notice not to be effective until the sixty-first day after the date such notice is delivered to the Issuer).
The responses of each of the Reporting Persons with respect to Rows 7, 8, 9, and 10 of the cover pages of this Schedule 13D that relate to the number of Class A Ordinary Shares as to which each of the Reporting Persons has sole or shared power to vote or to direct the vote of and sole or shared power to dispose of or to direct the disposition of (including but not limited to footnotes to such information) are incorporated herein by reference. 6,552,725 Class A Ordinary Shares and Private Placement Warrants exercisable into 13,146,346 Class A Ordinary Shares are held directly by AIB and may be deemed to be beneficially owned by AIM, AIH and Mr. Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AIB. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities.
The information set forth in Item 3 hereof is incorporated herein by reference.
Not applicable.
Not applicable.